Wearables flag heart failure
A recent study shows wearables using pVO2 metrics can predict heart‑failure risk and flag deterioration before symptoms appear — extending preventive monitoring beyond clinics (alltoc.com). Market research notes Garmin, Samsung, Huawei and Xiaomi are leading innovations and expect strong wearable‑heart market growth through 2033 (openpr.com).
Nature Medicine published the TRUE‑HF paper "Remote monitoring of heart failure exacerbations using a smartwatch" online March 20, 2026, reporting an observational cohort followed for a median 94.5 days and using consumer smartwatch data. (nature.com) The study split 217 participants into a training set of 154 and a held‑out validation set of 63 and trained a deep‑learning model to produce daily wearable‑derived pVO2 that correlated with in‑clinic CPET pVO2 with Pearson r = 0.85. (nature.com) In the primary cohort, each 10% drop in wearable‑derived daily pVO2 was linked to a 3.62‑fold higher hazard of unplanned healthcare events (95% CI 1.37–9.55; P < 0.01), with events occurring a median 7.4 days after the first 10% drop. (nature.com) Those findings were externally validated in an All of Us Research Program cohort using a reduced‑sensor cross‑platform model, where a 10% pVO2 drop carried an adjusted hazard ratio of 1.32 (95% CI 1.03–1.69) and events occurred a median 21 days after the initial drop. (nature.com) Market research places wearable heart‑monitor market expansion through the next decade: GII Research projects the market will grow from about USD 4.03 billion in 2025 to USD 10.12 billion by 2033 (CAGR ~12.2% for 2026–2033). (giiresearch.com) Other industry reports and vendor lists used in those forecasts identify Garmin, Samsung, Huawei and Xiaomi among the major players in wearable heart monitoring, and Omdia data reported Xiaomi reclaimed the global wearable band shipment lead in 2025 with roughly 18% market share while Samsung and Garmin accounted for about 9% and 5% respectively. (thebusinessresearchcompany.com) (businesswire.com) Prospective work is already registered: ClinicalTrials.gov lists NCT07350759, a pilot observational study seeking to develop algorithms to predict congestive heart‑failure decompensation using continuous wearable data with participants monitored for up to 12 months. (clinicaltrials.gov)
